EX-99.1 2 qttb-ex99_1.htm EX-99.1 EX-99.1 Q32 Bio Reports Second Quarter 2026 Financial Results and Provides Corporate Update -- Reported positive bempikibart 36-week topline results from Part B of SIGNAL-AA clinical trial; additional details from 36-week results and initial findings from 52-week results to be presented at a medical conference in the second half of 2026 -- -- Patient enrollment and dosing in SIGNAL-AA Part B open-label extension (OLE) ongoing -- -- Registration-directed program evaluating bempikibart in patients with severe or very severe AA expected to initiate in 1H’2027 subject to planned regulatory discussions later this year -- -- Half-life extended fully human anti-IL-7Rα antibody, ADX-914-XL, advancing in pre-clinical development -- -- Completed $200 million public offering in July 2026 -- -- Cash and cash equivalents of $106.3 million as of June 30, 2026, combined with proceeds from July 2026 public offering, are expected to provide financial runway through Phase 3 topline results from planned registration-directed program -- WALTHAM, Mass. - August 5, 2026 - Q32 Bio Inc. (Nasdaq: QTTB) (“Q32 Bio”), a clinical stage biotechnology company focuse…
Open exhibit ↗Current Report · Items 2.02, 9.01 · 8-K
Q32 Bio Inc.
QTTBNASDAQEQUITYCurrent
Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition. On August 5, 2026, Q32 Bio Inc. announced its financial results for the quarter ended June 30, 2026 and provided a corporate update. A copy of the press release in connection with the announcement is being furnished as Exhibit 99.1 to this Current Report on Form 8-K.…
Company context
Q32 Bio is a clinical-stage biotechnology company whose science targets potent regulators of the adaptive immune system to re-balance immunity and is focused on developing innovative therapies for alopecia areata and other autoimmune and inflammatory diseases. About 700,000 people in the United States live with alopecia areata1, a disease which has a life-altering impact on patients and limited current treatment options. Q32 Bio is advancing bempikibart (ADX-914), a fully human anti-IL-7Rα antibody that re-regulates adaptive immune function, for the treatment of alopecia areata in an ongoing Phase 2 program. The IL-7 and TSLP pathways have been genetically and biologically implicated in driving several T cell-mediated pathological processes in numerous autoimmune diseases.